5-fluorouracil + dacarbazine + mitomycin C

This is a combination chemotherapy regimen consisting of three cytotoxic agents—5-fluorouracil (5-FU), dacarbazine (DTIC), and mitomycin C. Each drug has a distinct mechanism of action targeting rapidly dividing cancer cells. - **5-Fluorouracil** is a pyrimidine analog antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis and function[4]. - **Dacarbazine** is an alkylating agent that acts as a prodrug; it undergoes metabolic activation to form methyl diazonium ions which methylate DNA, leading to inhibition of DNA replication and cell death[5]. - **Mitomycin C** is an antitumor antibiotic that acts as an alkylating agent after enzymatic activation, causing cross-linking of DNA strands and inhibiting DNA synthesis. This combination has been studied in advanced colorectal cancer[1][2], with the rationale being potential synergistic effects from combining drugs with different mechanisms. However, clinical studies have shown limited improvement over single-agent therapy with increased gastrointestinal toxicity[2].

Other names

5-FU + DTIC + MMC5-fluorouracil, dacarbazine and mitomycin C combination